Chi­na’s Yisheng­Bio is go­ing to Nas­daq, mak­ing the tran­si­tion via $230M SPAC ma­neu­ver

Af­ter at­tempt­ing to make it on the HKEX last year, a Chi­nese bio­phar­ma is fi­nal­ly tak­ing the once-flashy SPAC route to get on the Nas­daq.

Yisheng­Bio — which will be re­named YS Bio­phar­ma, per a Thurs­day state­ment — will be com­bin­ing with Hong Kong-based Sum­mit Health­care Ac­qui­si­tion Corp, cur­rent­ly list­ed on Nas­daq un­der the tick­er $SMIH af­ter launch­ing on the stock ex­change last year. If every­thing goes to plan, the merg­er will be fin­ished in Q1 next year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER